[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337748-105":59,"doc-detail-337748-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prospects-of-liquid-biopsy-in-the-prognosis-and-clinical-management-of-gastrointestinal-cancers","Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers","","Gastrointestinal (GI) cancers account for a substantial share of global incidence and cancer mortality, with most cases detected at advanced stages due to limited early-stage biomarkers. Colonoscopy-based solid biopsies are invasive and reduce patient compliance, motivating minimally invasive alternatives. Liquid biopsy detects qualitative and quantitative cancer-specific biomarkers in blood, serum, saliva, and urine to estimate progression, treatment tolerance, toxicities, and recurrence. This review discusses tumor-specific entities including CTCs, TEPs, ctDNA, cfDNA, exosomes, and exosome-derived molecules, and summarizes technical barriers to clinical translation for GI cancer applications.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prospects-of-liquid-biopsy-in-the-prognosis-and-clinical-management-of-gastrointestinal-cancers/337748/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prospects-of-liquid-biopsy-in-the-prognosis-and-clinical-management-of-gastrointestinal-cancers/337748.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is liquid biopsy considered for gastrointestinal cancer screening and early identification?","Question",{"text":113,"@type":114},"GI cancers are often diagnosed at advanced stages because early-stage biomarkers are lacking. Liquid biopsy is minimally invasive and can evaluate biomarkers in body fluids for screening and early identification.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which biomarkers are discussed in relation to liquid biopsy in GI cancers?",{"text":118,"@type":114},"The review addresses circulating tumor cells (CTCs), tumor-educated platelets (TEPs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), exosomes, and exosome-derived biomolecules.",{"name":120,"@type":111,"acceptedAnswer":121},"What clinical decisions can liquid biopsy biomarkers help support?",{"text":122,"@type":114},"Liquid biopsy may be used to predict disease progression, therapeutic tolerance, treatment-related toxicities, and recurrence by assessing minimal residual disease and its relationship with other clinical features.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337748,1790090967,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":26},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","TYPE Review  \nPUBLISHED 06 May 2024  \nDOI 10.3389/fmolb.2024.1385238  \nOPEN ACCESS  \nEDITED BY  \nAshok Kumar,  \nAll India Institute of Medical Sciences, India  \nREVIEWED BY  \nTaha Resid Özdemir,  \nHealth Sciences University, Türkiye Asha Thomas,  \nCase Western Reserve University, United States  \n*CORRESPONDENCE  \nDhananjay Shukla,  \n [sdhannu@gmail.com](sdhannu@gmail.com)  \nRECEIVED 12 February 2024  \nACCEPTED 08 April 2024  \nPUBLISHED 06 May 2024  \nCITATION  \nMondal D, Shinde S, Sinha V, Dixit V, Paul S, Gupta RK, Thakur S, Vishvakarma NK and Shukla D (2024), Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.  \nFront. Mol. Biosci. 11:1385238 .  \ndoi: 10.3389/fmolb.2024.1385238  \nCOPYRIGHT  \n© 2024 Mondal, Shinde, Sinha, Dixit, Paul, Gupta, Thakur, Vishvakarma and Shukla. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nProspects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers  \nDeepankar Mondal 1, Sapnita Shinde 1, Vibha Sinha 1, Vineeta Dixit 2, Souvik Paul 3, Rakesh Kumar Gupta 4, Suresh Thakur 5,  \nNaveen Kumar Vishvakarma 1 and Dhananjay Shukla 1*  \n1Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India, 2Department of Botany, Sri Sadguru Jagjit Singh Namdhari College, Garhwa, Jharkhand, India, 3Department of Surgical Gastroenterology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India, 4Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India, 5Trivitron Healthcare Pvt Ltd., Chennai, India  \nGastrointestinal (GI) cancers account for one-fourth of the global cancer incidence and are incriminated to cause one-third of cancer-related deaths. GI cancer includes esophageal, gastric, liver, pancreatic, and colorectal cancers, mostly diagnosed at advanced stages due to a lack of accurate markers for early stages. The invasiveness of diagnostic methods like colonoscopy for solid biopsy reduces patient compliance as it cannot be frequently used to screen patients. Therefore, minimally invasive approaches like liquid biopsy may be explored for screening and early identification of gastrointestinal cancers. Liquid biopsy involves the qualitative and quantitative determination of certain cancerspecific biomarkers in body fluids such as blood, serum, saliva, and urine to predict disease progression, therapeutic tolerance, toxicities, and recurrence by evaluating minimal residual disease and its correlation with other clinical features. In this review, we deliberate upon various tumor-specific cellular and molecular entities such as circulating tumor cells (CTCs), tumor-educated platelets (TEPs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), exosomes, and exosomederived biomolecules and cite recent advances pertaining to their use in predicting disease progression, therapy response, or risk of relapse. We also discuss the technical challenges associated with translating liquid biopsy into clinical settings for various clinical applications in gastrointestinal cancers.  \nKEYWORDS  \ncolorectal cancer, gastrointestinal cancers, liquid biopsy, prognosis, circulating tumor cells, clinical applications  \n1 Introduction  \nGastrointestinal (GI) cancers, encompassing colorectal, stomach, esophageal, liver, and pancreatic cancers, exhibit varying global incidences and mortality rates (Siegel et al., 2023a) . A recent estimate reports that gastrointestinal cancers contribute to one in three cancer incidences and one in three cancer-related deaths globally and","cbCaimtfGG5OsoPz","https://ap.wps.com/l/cbCaimtfGG5OsoPz","pdf",2522168,24,"English","# Introduction\n# Liquid biopsy biomarkers and tumor-specific entities\n# Clinical applications in GI cancer prognosis and management\n## Prognosis, recurrence risk, and minimal residual disease\n## Therapy response, toxicity, and treatment tolerance\n# Technical challenges and clinical translation","[{\"question\":\"Why is liquid biopsy considered for gastrointestinal cancer screening and early identification?\",\"answer\":\"GI cancers are often diagnosed at advanced stages because early-stage biomarkers are lacking. Liquid biopsy is minimally invasive and can evaluate biomarkers in body fluids for screening and early identification.\"},{\"question\":\"Which biomarkers are discussed in relation to liquid biopsy in GI cancers?\",\"answer\":\"The review addresses circulating tumor cells (CTCs), tumor-educated platelets (TEPs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), exosomes, and exosome-derived biomolecules.\"},{\"question\":\"What clinical decisions can liquid biopsy biomarkers help support?\",\"answer\":\"Liquid biopsy may be used to predict disease progression, therapeutic tolerance, treatment-related toxicities, and recurrence by assessing minimal residual disease and its relationship with other clinical features.\"}]","Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers | PDF",1790020475]